{
    "clinical_study": {
        "@rank": "55153", 
        "arm_group": [
            {
                "arm_group_label": "UCBMC, surgery", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood unit"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "The control group will receive standard treatment which does not involve interventional treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is to assess the safety and possible efficacy of umbilical cord blood mononuclear\n      cells (UCBMC) treatment of chronic ischemic stroke."
        }, 
        "brief_title": "Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stroke", 
            "Ischemic Stroke", 
            "Brain Ischemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Ischemia", 
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label randomized controlled study.  Subjects fulfill the inclusion and\n      exclusion criteria will be recruited and randomly assigned to treatment group or control\n      group.  The subjects in the treatment group will receive transplant of UCBMC isolated from\n      HLA-matched cord blood unit.  The subjects in the control group will receive standard\n      routine treatment which do not involve interventional treatment.  All subjects will be\n      followed up for at least 12 months.  Long-term follow-up will be carried up to 36 months if\n      applicable.\n\n      The adverse events and safety parameters will be record and assessed.  In addition, the\n      stroke scores , gait and brain MRI will be obtained before and after the treatment to assess\n      the safety and potential treatment effect of UCBMC in chronic ischemic stroke."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  either gender, age 35 -65 years old;\n\n          -  ischemic stroke > 6 months and < 60 months;\n\n          -  stable hemiplegia or hemiparesis condition > 3 months;\n\n          -  stroke-induced clinical deficits affecting motor, perceptual, or language functions,\n             with NIHSS of 5-15;\n\n          -  stroke in the middle cerebral artery territory;\n\n          -  subjects able to understand, sign and date the informed consent form\n\n        Exclusion Criteria:\n\n          -  non-ischemic mechanism, subarachnoid hemorrhage, primary intracerebral or\n             intraventricular hemorrhage;\n\n          -  pregnant or lactating women;\n\n          -  alcohol or drug abuse in previous 3 months;\n\n          -  significant medical diseases or infections;\n\n          -  current participation in another investigational study or taking any investigational\n             drug within last 4 weeks before the screening;\n\n          -  unavailability of HLA-matched umbilical cord blood unit;\n\n          -  investigator suggests that the subject would not suitable to perform the surgery or\n             participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01673932", 
            "org_study_id": "UCB-IS-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "UCBMC, surgery", 
                "description": "Inject 10-40 million viable UCBMC (umbilical cord blood mononuclear cells) suspension into brain adjacent to the infract", 
                "intervention_name": "UCBMC", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "UCBMC, surgery", 
                "intervention_name": "surgery", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "stroke", 
            "chronic stroke", 
            "ischemic stroke", 
            "umbilical cord blood", 
            "umbilical cord blood mononuclear cells", 
            "transplant"
        ], 
        "lastchanged_date": "April 22, 2013", 
        "location": [
            {
                "contact": {
                    "email": "mykiang@hku.hk", 
                    "last_name": "Karrie Kiang", 
                    "phone": "+852 2255 4468"
                }, 
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Queen Mary Hospital"
                }, 
                "investigator": {
                    "last_name": "Gilberto Ka Kit Leung, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "stroke-study@surgery.cuhk.edu.hk", 
                    "last_name": "Waisang Poon, MD", 
                    "phone": "+852 2632 1625"
                }, 
                "facility": {
                    "address": {
                        "city": "Shatin", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Prince of Wales Hospital"
                }, 
                "investigator": {
                    "last_name": "Waisang Poon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Hong Kong"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1 Clinical Trial to Establish the Safety and Feasibility of Transplants of Umbilical Cord Blood Mononuclear Cells in Chronic Ischemic Stroke", 
        "overall_official": [
            {
                "affiliation": "The Chinese University of Hong Kong, Prince of Wales Hospital", 
                "last_name": "Waisang Poon, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The University of Hong Kong, Queen Mary Hospital", 
                "last_name": "Gilberto Ka Kit Leung, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Hong Kong: Ethics Committee", 
                "Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The change from the baseline in National Institutes of Health Stroke Scales", 
                "measure": "National Institutes of Health Stroke Scale", 
                "safety_issue": "Yes", 
                "time_frame": "12 months, up to 36 months"
            }, 
            {
                "description": "The primary endpoint will be the safety of UCBMC treatment as determined by the incidence and severity of adverse events, clinically-significant changes on clinical laboratory tests, vital signs, physical and neurological examinations.", 
                "measure": "Primary Safety Outcome", 
                "safety_issue": "Yes", 
                "time_frame": "12 months, up to 36 months followup"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01673932"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The change from baseline in ESS", 
                "measure": "European Stroke Scale (ESS)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months, up to 36 months if applicable"
            }, 
            {
                "measure": "Barthel Index", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The change from baseline in MMSE", 
                "measure": "Min-Mental State Examination (MMSE)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The change in MRI between pre-treatment and post-treatment", 
                "measure": "MRI", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "China Spinal Cord Injury Network", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Chinese University of Hong Kong", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The University of Hong Kong", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Prince of Wales Hospital, Shatin, Hong Kong", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Queen Mary Hospital, Hong Kong", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "StemCyte, Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "China Spinal Cord Injury Network", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}